Sen. Bill Cassidy (R-La.) on Sunday said there are still questions left unanswered about Heidi Overton, President Trump’s pick to lead the Food and Drug Administration (FDA), ahead of the Senate Health Committee’s vote on her nomination this week.

CBS News’s Margaret Brennan asked Cassidy during his appearance on “Face the Nation” if Overton will be approved with Wednesday’s vote, noting how the senator said her role in reshaping the Trump administration’s vaccine policies were “almost disqualifying.”

“I don’t know that,” Cassidy, who chairs the health committee, said Sunday. “I’ve been working the phones all week. Both speaking with Dr. Overton, speaking with others. I still have questions. And so, I cannot tell you the outcome of that vote right now. But I spoke to four or five of my down-dais Republican members, as well as continuing to discuss things with my advisers. So, I can’t tell you that answer yet.”

Brennan asked if he might leave the Senate in January without an FDA commissioner in place and if that worried him. Cassidy said yes, “but we’re not going to have perfection.”

“So, then the question is, do we want a series of short-term administrators who probably will have more influence from the secretary, as opposed to someone who may be not, you know, the perfect candidate in somebody’s mind but at least would be a permanent one and have the ability to establish some independence,” the Louisiana Republican continued.

Next

Stay
Cassidy added that he “heard from a lot of people who are significant –– who think deeply about the FDA, who have said it’s better to have a steady hand,” though others have offered a “different opinion.”

Overton pushed back on Trump’s false claims that the measles, mumps and rubella (MMR) vaccine could be dangerous and said at her September confirmation hearing that the vaccine was “safe and effective.”

Republicans are racing to confirm as many of Trump’s nominees before Democrats take power next year. But the GOP has just a single vote majority on the panel, so losing one member would be enough to sink the nomination if all Democrats oppose it.

Cassidy previously said he met with Overton last Tuesday but remained undecided. He seemingly tied her and National Science Foundation nominee Jim O’Neill to promises Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. made in locking the deciding vote from Cassidy before his own confirmation, which have since been broken.

Overton is a top domestic policy adviser at the White House and a former chief policy adviser at a conservative think tank. If confirmed, the openly anti-abortion Overton would inherit the FDA’s safety review of the abortion pill mifepristone.

Trump nominated Overton about three months after the resignation of former FDA Commissioner Marty Makary, Trump’s first confirmed pick to lead the agency.